Gene VEGFR2
Back to Curriculum
Also known as
Vascular endothelial growth factor receptor 2, KDR, FLK1, CD309Overview
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), also known as KDR or FLK1, encodes the primary receptor mediating VEGF-induced angiogenesis. This receptor tyrosine kinase is predominantly expressed on vascular endothelial cells and serves as the main signaling receptor for VEGFA. Upon VEGF binding, VEGFR2 undergoes dimerization and autophosphorylation, initiating signaling cascades that promote endothelial cell proliferation, migration, survival, and vascular permeability.Genetic variants in VEGFR2 influence receptor expression levels, ligand binding affinity, and downstream signaling intensity. These polymorphisms have been associated with differences in angiogenic capacity, exercise-induced capillary growth, and cardiovascular function. In athletic contexts, certain VEGFR2 genotypes may enhance training-induced improvements in muscle blood flow and oxygen delivery, potentially benefiting endurance performance. The gene has also been linked to hypertension risk and cardiovascular disease susceptibility.
In dermatological contexts, VEGFR2 signaling influences wound healing, skin vascularity, and conditions like rosacea and port-wine stains. The receptor is also a major therapeutic target in cancer treatment, with multiple anti-VEGFR2 drugs approved for various malignancies. Understanding VEGFR2 genetics can inform personalized approaches to athletic training, cardiovascular health management, and skincare strategies.